EU approves Revlimid (Celgene) for transfusion dependent anaemia associated with Myelodysplastic Syndromes

The European Commission has amended the marketing authorisation for Revlimid (lenalidomide)from Celgene.This decision means that Revleimd is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

In addition to the European Commission decision for EMEA, Revlimd is approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.